Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol

Barbara Buldini, Frida Rizzati, Riccardo Masetti, Franca Fagioli, Giuseppe Menna, Concetta Micalizzi, Maria Caterina Putti, Carmelo Rizzari, Nicola Santoro, Marco Zecca, Silvia Disarò, Roberto Rondelli, Pietro Merli, Martina Pigazzi, Andrea Pession, Franco Locatelli, Giuseppe Basso

Research output: Contribution to journalArticle

Abstract

In children with acute myeloid leukaemia (AML), assessment of initial treatment response is an essential prognostic factor; methods more sensitive than morphology are still under evaluation. We report on the measurement of minimal residual disease (MRD), by multicolour flow-cytometry in one centralized laboratory, in 142 children with newly diagnosed AML enrolled in the Associazione Italiana di EmatoOncologia Pediatrica-AML 2002/01 trial. At the end of the first induction course, MRD was 1% in 51 patients. The 8-year disease-free survival (DFS) of 125 children in morphological complete remission and with MRD
Original languageEnglish
Pages (from-to)116-126
Number of pages11
JournalBritish Journal of Haematology
Volume177
Issue number1
DOIs
Publication statusPublished - Apr 1 2017

    Fingerprint

Keywords

  • Acute myeloid leukaemia
  • Flow-cytometry
  • Minimal residual disease
  • Paediatric; Risk group

Cite this

Buldini, B., Rizzati, F., Masetti, R., Fagioli, F., Menna, G., Micalizzi, C., Putti, M. C., Rizzari, C., Santoro, N., Zecca, M., Disarò, S., Rondelli, R., Merli, P., Pigazzi, M., Pession, A., Locatelli, F., & Basso, G. (2017). Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. British Journal of Haematology, 177(1), 116-126. https://doi.org/10.1111/bjh.14523